There are currently no FDA-approved CDx for allogenic cell therapies (ACTs) but a recently published article by The College of American Pathologists (CAP) highlighted patient selection and compatibility as a potential challenge in the development and implementation of ACTs. They say that “HLA matching of the allogeneic cell product may be required to avoid GvHD [graft versus host disease] or to ensure efficacy.”
For the full article click here: Unpacking the Complexities of Companion Diagnostics for Cell and Gene Therapies